Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer-Reference-Cited by-同舟云学术

Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer

Published:2017-10-06 Issue:4 Volume:59 Page:625-631
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Hofman Michael S.,Eu Peter,Jackson Price,Hong Emily,Binns David,Iravani Amir,Murphy Declan,Mitchell Catherine,Siva Shankar,Hicks Rodney J.,Young Jennifer D.,Blower Philip J.,Mullen Gregory E.

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference17 articles.

1. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

2. Prostate-specific membrane antigen expression in normal and malignant human tissues;Silver;Clin Cancer Res.,1997

3. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

4. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer

5. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [⁶⁸Ga]Ga-THP-tetrazine for bioorthogonal click radiolabelling: pretargeted PET imaging of liposomal nanomedicines;RSC Chemical Biology;2024

2. PSMA Targeted Ligands in Imaging and Theranostics for Prostate Cancer;The Bulletin of Urooncology;2023-12-04

3. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides;Chemical Reviews;2023-10-05

4. Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE;European Journal of Nuclear Medicine and Molecular Imaging;2023-06-26

5. [⁶⁸Ga]Ga-HBED-CC-FAPI Derivatives with Improved Radiolabeling and Specific Tumor Uptake;Molecular Pharmaceutics;2023-03-21